Regenerative Medicine for Sexual Health
The Cash-Pay Clinic Landscape: Shockwave, PRP, Stem Cells, Exosomes & the Evidence-vs-Hype Gap
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No regenerative therapy is FDA-approved for ED; most are investigational or unapproved
Reference only. Not medical advice.
What can go wrong
Direct physical risk of most of these procedures is generally modest (bruising, transient pain, infection risk at injection sites). The larger harms are financial (thousands of dollars for unproven treatment), opportunity cost (delaying evaluation of the real vascular, hormonal, or psychological cause of ED), and, at the fraudulent end (unregulated stem cells, exosomes injected as biologics), documented serious adverse events including infection and, in a non-genital stem-cell case, blindness.
This is something to take to a clinician. The Atlas can tell you what is known about regenerative medicine for sexual health in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Regenerative medicine for sexual health is a cluster of cash-pay procedures marketed to restore erectile function (and, in the marketing, to enlarge the penis or boost performance): low-intensity shockwave therapy, platelet-rich plasma injection (the trademarked 'P-Shot'), stem-cell injection, exosome infusion, and amniotic/placental products. The unifying honest fact is that as of 2026 none is FDA-approved for erectile dysfunction, and the professional-society position (AUA 2018; SMSNA) is that all should be considered investigational or experimental and offered only within clinical trials. The recurring pattern is a real but early mechanistic hypothesis (neovascularization, growth-factor signaling), one or two small positive sham-controlled trials, and then a large, aggressive, out-of-pocket marketing apparatus that outruns the data. Enlargement and 'performance' claims in particular have no controlled evidence.
A field where the marketing runs years ahead of the randomized trials.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The shared premise is 'restorative' rather than 'on-demand': instead of enabling an erection in the moment like a PDE5 inhibitor, these therapies claim to modify the underlying tissue by driving angiogenesis (new blood-vessel growth), improving endothelial function, recruiting progenitor cells, or delivering growth factors. Each modality has a distinct proposed mechanism, but they share the same evidentiary weakness: the biological plausibility is real in animal and bench models, while durable disease-modification in humans remains largely unproven.
The catch: the business model is built on the gap
The economic structure of the field selects for marketing ahead of evidence. Because these are cash-pay procedures not covered by insurance, revenue depends on volume and repeat sessions rather than on demonstrated durability. Devices and kits cleared by the FDA for unrelated indications (orthopedic soft-tissue, general blood-flow, wound care) are re-marketed for sexual health, and clearance for one purpose is presented as if it were approval for ED. Trademarked branded protocols (the P-Shot, GAINSWave provider networks) add a licensing layer on top. The result is a marketplace where 'FDA cleared,' 'regenerative,' 'natural,' and 'drug-free' function as sales language rather than efficacy claims.
What people get wrong
Often saidThese are proven 'regenerative' cures for ED
ActuallyNone is FDA-approved for ED. The AUA and SMSNA classify shockwave, PRP, and stem-cell therapy as investigational or experimental and recommend they be offered only within clinical trials.
Often said'FDA cleared' means the FDA approved it for ED
ActuallyClearance and approval are different. The devices/kits are typically cleared (510(k)) for orthopedic soft tissue or general blood flow, not approved for erectile dysfunction. Marketing conflates the two.
Often saidRegenerative therapy makes you bigger
ActuallyNo controlled trial shows any of these therapies increases penile length or girth. Enlargement claims are marketing, not data.
Who profits, and who pushes back
American Urological Association
Restorative therapies including shockwave, PRP, and stem cells should be considered investigational and used only in the setting of clinical trials.
Sexual Medicine Society of North America
There is an absence of robust clinical data supporting the efficacy of restorative therapies for ED.
The money flows to device manufacturers (focused and radial shockwave units), PRP-kit and centrifuge makers, trademark licensors (monthly per-provider fees for branded protocols), provider networks that sell leads and directory listings to clinics, and the clinics themselves, which bill entirely out of pocket. Because insurance does not cover these, pricing is set by what the market will bear, not by cost or demonstrated value.
What we do not know
- Which patients, if any, get durable benefit rather than a transient or placebo effect?
- Can any modality be standardized enough (energy, dose, timing) to run a definitive pivotal trial?
- Will regulators act on the cash-pay marketing of unapproved biologics as they have on non-genital stem-cell clinics?
At a glance
- FDA-approved for ED
- None of these therapies
- AUA 2018 stance
- Investigational / experimental
- Typical payment
- Cash-pay, out of pocket
- Enlargement evidence
- None (controlled trials)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Regenerative Medicine for Sexual Health. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.